TAS2R38: A Potential Drug Target and Biomarker for Taste and Liquid Sensory Systems

Target Name: TAS2R38

NCBI ID: G5726

TAS2R38

TAS2R38: A Potential Drug Target and Biomarker for Taste and Liquid Sensory Systems

Abstract:

TAS2R38, a G protein-coupled receptor (GPCR), is a member of the Taste Receptor Type 2 (TAS2R2) family, which plays a crucial role in mediating the sense of taste and texture in food. The TAS2R38 gene has been implicated in various taste and liquid sensory processes, and its expression has been linked to various diseases, including obesity, diabetes, and neurodegenerative disorders. This review summarizes the current understanding of TAS2R38, its potential drug targets, and its role as a biomarker in various disease states.

Introduction:

Taste and liquid sensory systems are critical aspects of human nutrition and quality of life. The sense of taste and texture are closely associated with the consumption of food, and their perception is mediated by various chemical and neural interactions. The TAS2R2 family, which includes TAS2R38, is a GPCR that has been identified as a key regulator of taste and texture perception. TAS2R38 is expressed in various tissues, including the tongue, brain, and gut, and its expression has been linked to various diseases, including obesity, diabetes, and neurodegenerative disorders.

Drug Targets:

TAS2R38 is a potential drug target for various diseases due to its involvement in various signaling pathways that are associated with various diseases. The following are some of the potential drug targets for TAS2R38:

1. Obesity: TAS2R38 is involved in the modulation of food intake and body weight, and its overexpression has been linked to obesity. Therefore, TAS2R38 could be a potential target for anti-obesity drugs.
2. Diabetes: TAS2R38 is involved in the regulation of glucose tolerance and metabolism, and its overexpression has been linked to insulin resistance and glucose intolerance. Therefore, TAS2R38 could be a potential target for anti-diabetic drugs.
3. Neurodegenerative Disorders: TAS2R38 has been implicated in the development and progression of various neurodegenerative disorders, including Alzheimer's disease and Parkinson's disease. Therefore, TAS2R38 could be a potential target for neurodegenerative disease treatments.

Biomarkers:

TAS2R38 has also been suggested as a potential biomarker for various diseases. The following are some of the potential biomarkers for TAS2R38:

1. taste acuity: TAS2R38 is involved in the modulation of taste perception, and its overexpression has been linked to improved taste acuity. Therefore, TAS2R38 could be a potential biomarker for taste perception.
2. food intake: TAS2R38 is involved in the regulation of food intake, and its overexpression has been linked to increased food intake. Therefore, TAS2R38 could be a potential biomarker for food intake.
3. body weight: TAS2R38 is involved in the regulation of body weight, and its overexpression has been linked to increased body weight. Therefore, TAS2R38 could be a potential biomarker for body weight.

Conclusion:

TAS2R38 is a GPCR that has been identified as a key regulator of taste and texture perception. Its expression has been linked to various diseases, including obesity, diabetes, and neurodegenerative disorders. Therefore, TAS2R38 is a potential drug target and biomarker for various diseases. Further research is needed to fully understand the role of TAS2R38 in

Protein Name: Taste 2 Receptor Member 38

Functions: Receptor that may play a role in the perception of bitterness and is gustducin-linked. May play a role in sensing the chemical composition of the gastrointestinal content. The activity of this receptor may stimulate alpha gustducin, mediate PLC-beta-2 activation and lead to the gating of TRPM5 (By similarity)

The "TAS2R38 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about TAS2R38 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets